Andersen, Mikael Rørdam

Knudsen, Cecilie

Laustsen, Andreas Hougaard

Lohse, Brian

With an annual 150,000 deaths and countless amputations and disfigurements,snakebite envenoming is an ever-present threat in many parts of the rural tropicalworld1. In sub-Saharan Africa, only 1-2% of victims are treated with antivenom,which is currently based on animal-derived antibodies. Due to their heterologousorigin, antivenoms often provoke serious side effects in human recipients, such asserum sickness and anaphylaxis, which in some cases leads to death

Online Research Database In Technology

                       General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.  • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal   If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.     Downloaded from orbit.dtu.dk on: Dec 18, 2017Development of recombinant antivenoms based on mixtures of human antibodiesagainst D. polylepis toxinsKnudsen, Cecilie; Andersen, Mikael Rørdam; Lohse, Brian; Laustsen, Andreas HougaardPublication date:2016Document VersionPublisher's PDF, also known as Version of recordLink back to DTU OrbitCitation (APA):Knudsen, C., Andersen, M. R., Lohse, B., & Laustsen, A. H. (2016). Development of recombinant antivenomsbased on mixtures of human antibodies against D. polylepis toxins. Poster session presented at ProteinInteractions Workshop, Kgs. Lyngby, Denmark.Development of recombinant antivenoms based on mixtures of human antibodies against D. polylepis toxinsCecilie Knudsen1, Mikael R. Andersen1, Brian Lohse2, Andreas H. Laustsen1,21Department of Biotechnology and Biomedicine, Technical University of Denmark2Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of CopenhagenReferences[1] WHO, http://www.who.int/mediacentre/factsheets/fs337/en/[2] Brown NI: Consequences of neglect: Analysis of the sub-Saharan African snakeantivenom market and the global context. PLoS Negl. Trop. Dis. 2012, 6.[3] Gutierrez JM, Leon G, Lomonte B, Angulo Y. (2011) Antivenoms for snakebiteenvenomings. Inflammation & Allergy-Drug Targets 10(5): 369-80.[4] Laustsen AH: Toxin synergism in snake venoms. Toxin Rev. 2016, 35:165–170.Dtx58 %3FTx29 %Contactnzj892@alumni.ku.dkAcknowledgementsWe thank the Novo Nordisk Foundation (NNF16OC0019248), Symphogen A/S, and the Oticon Foundation for financial support. Clinical manifestations of D. polylepis toxinsD. polylepisThe snakebite challengeWith an annual 150,000 deaths and countless amputations and disfigurements,snakebite envenoming is an ever-present threat in many parts of the rural tropicalworld1. In sub-Saharan Africa, only 1-2% of victims are treated with antivenom2,which is currently based on animal-derived antibodies. Due to their heterologousorigin, antivenoms often provoke serious side effects in human recipients, such asserum sickness and anaphylaxis, which in some cases leads to death3.Selection of high-affinity human scFvs by phage displayFuture: Human recombinant oligoclonal antivenomsThe aim of this research is to enable the production of modern, fully recombinant,oligoclonal antivenoms consisting of specifically selected human IgG antibodies withproven specificity against medically relevant D. polylepis toxins. It is the hope thatresults obtained during this study will help pave the way for cost-effective recombinantantivenoms with better safety and efficacy for treatment of snakebite envenoming insub-Saharan Africa.scFvIgG scaffold Human IgGscFv to IgG conversionNP9%α-neurotoxinnAChRExtracellularIntracellularCa2+Na+Ca2+Na+Flaccid paralysisRespiratory failureDendrotoxinK+ channelExtracellularIntracellularFasciculationsExcited stateK+K+Acetylcholine vesicle1. Panning4. Elution5. AmplificationRepeatAnalyze6. ELISA2. Binding 3. WashingD. polylepis venom composition and actionsThe potency of the venom of D.polylepis, is derived from thesynergism between type I and II α-neurotoxins and dendrotoxins,which target nicotinic acetylcholinereceptors and potassium channels,respectively, causing involuntarymuscle contractions, flaccidparalysis, and death4.Cultivation and purificationParallel batchCultivation and purificationOligoclonal batchStrategies for expression of antibody mixturesCHO cell expression

Development of recombinant antivenoms based on mixtures of human antibodies against <i>D. polylepis</i> toxins

http://orbit.dtu.dk/ws/files/127390215/Development_of_recombinant_antivenoms_based_on_mixtures_of_human_antibodies_against_D._polylepis_toxins.pdf

Development of recombinant antivenoms based on mixtures of human antibodies against <i>D. polylepis</i> toxins

Abstract

Similar works

Full text

Available Versions

Online Research Database In Technology